Assisted Reproductive Technology through Artificial Intelligence

By Sumona Bose

March 6, 2024

Introduction

Since the first successful in vitro fertilisation (IVF) birth in 1978, assisted reproductive technology (ART) has advanced, aiding over eight million infertile couples in conceiving. The intricate protocols of IVF involve critical decision-making points handled by clinicians and embryologists, blending evidence-based choices with subjective judgments, shaping ART as both science and art. Artificial intelligence (AI) offers a promising avenue for optimising ART processes like drug selection, cycle monitoring, and embryo selection. Could this be a beginning to a future of unbelievable progress in the field of reproductive health?

Personalising ART with Machine Learning

Customising ART based on individual factors like ovarian reserve, genetic variations, and ethnic disparities can significantly impact treatment success. Machine learning (ML) methods enable tailoring treatment regimens to patient subgroups, optimising ovarian response, and luteal phase support. The integration of ML algorithms into clinical decision support systems (CDSS) harnesses the potential of electronic health records, offering personalised and data-driven approaches to enhance ART outcomes. As shown in Figure 1, the procedures involving ART are intricate, demanding thorough supervision. Clinicians and embryologists bear the responsibility for numerous crucial decision junctures both before and throughout the treatment cycle. AI contributes to this complex process with its data analysis skills.

Figure 1: Potential targets for the application of artificial intelligence and ML methods during clinical and embryological steps in ART. The order and timings of the steps can differ depending on the ART protocol used.

Transparency and Trust in AI Applications

The adoption of AI in ART faces challenges related to trust and interpretability, especially with complex ‘black-box’ models. Transparency emerges as a crucial factor in AI systems to ensure clinicians’ confidence in decision-making tools. Efforts to enhance explainability in AI models, particularly in image-based analyses in embryology, aim to provide insights into model reliability, fairness, and trustworthiness, paving the way for more widespread and effective use of AI in reproductive healthcare.

Conclusion

The integration of AI technologies holds immense promise in ART, offering personalised, data-driven, and transparent solutions to enhance the success rates and safety of assisted reproduction procedures. The blend of science and art in ART, with its intricate protocols and subjective decision-making, sets the stage for AI to make significant advancements in this field.

Reference url

Recent Posts

suzetrigine pain management
      

Journavx for Pain Management: Toward Affordability and Access

💊 The jury is out on the pricing for Journavx®

Delve into our review of the recent ICER 2025 report on suzetrigine (Journavx®) to learn about the anticipated value relative to its clinical efficacy, safety profile and potential cost savings in tackling acute pain while addressing the opioid crisis.

Explore how suzetrigine paves the way for a safer, more effective approach to pain management and its implications on healthcare economics.

#SyenzaNews #HealthEconomics #HealthcareInnovation #Journavx

defunding scientific research
      

Defunding Scientific Research: Implications and Misconceptions in Gawande’s Analysis of Harvard Funding Cuts

🚨 What happens when scientific research funding is threatened?

In his thought-provoking article, Atul Gawande highlights the dire implications of proposed federal funding cuts to elite institutions like Harvard. He argues that such actions could devastate not just innovation, but also patient care and public health across the nation.

Explore the complexities of research funding and the potential ripple effects on America’s scientific landscape. Don’t miss out on these critical insights!

#SyenzaNews #HealthcareInnovation #HealthEconomics #MarketAccess

perioperative immunotherapy bladder cancer
       

FDA Approves Perioperative Immunotherapy for Bladder Cancer: A Breakthrough in MIBC Treatment

🚀 Are we witnessing a new era in bladder cancer treatment?

The FDA’s recent approval of durvalumab as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) could revolutionize outcomes for patients facing this formidable diagnosis. With significant improvements in event-free survival and overall survival over standard chemotherapy, this groundbreaking treatment offers new hope 🎉.

Curious about how this could shape the future of cancer care? Dive into the full article to uncover the potential impacts on clinical practice and health economics.

#SyenzaNews #oncology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.